vs
BOSTON OMAHA Corp（BOC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是BOSTON OMAHA Corp的1.0倍（$30.3M vs $29.7M），BOSTON OMAHA Corp净利率更高（-23.1% vs -221.3%，领先198.3%），REGENXBIO Inc.同比增速更快（43.0% vs 6.4%），BOSTON OMAHA Corp自由现金流更多（$-10.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 7.8%）
波士顿奥马哈公司是一家上市多元化控股企业，核心业务板块涵盖户外广告、担保保险、住宅地产开发、固定无线宽带服务，主要服务美国市场，通过战略收购与业务有机增长为股东创造长期价值。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BOC vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.0倍
$29.7M
营收增速更快
RGNX
高出36.7%
6.4%
净利率更高
BOC
高出198.3%
-221.3%
自由现金流更多
BOC
多$42.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $29.7M | $30.3M |
| 净利润 | $-6.9M | $-67.1M |
| 毛利率 | 64.0% | — |
| 营业利润率 | -4.2% | -190.0% |
| 净利率 | -23.1% | -221.3% |
| 营收同比 | 6.4% | 43.0% |
| 净利润同比 | -228.1% | -31.2% |
| 每股收益（稀释后） | $-0.23 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BOCRGNX
| Q4 25 | $29.7M | $30.3M | ||
| Q3 25 | $28.7M | $29.7M | ||
| Q2 25 | $28.2M | $21.4M | ||
| Q1 25 | $27.7M | $89.0M | ||
| Q4 24 | $27.9M | $21.2M | ||
| Q3 24 | $27.7M | $24.2M | ||
| Q2 24 | $27.1M | $22.3M | ||
| Q1 24 | $25.6M | $15.6M |
净利润BOCRGNX
| Q4 25 | $-6.9M | $-67.1M | ||
| Q3 25 | $-2.6M | $-61.9M | ||
| Q2 25 | $-2.3M | $-70.9M | ||
| Q1 25 | $-669.3K | $6.1M | ||
| Q4 24 | $5.3M | $-51.2M | ||
| Q3 24 | $-1.6M | $-59.6M | ||
| Q2 24 | $-2.2M | $-53.0M | ||
| Q1 24 | $-2.8M | $-63.3M |
毛利率BOCRGNX
| Q4 25 | 64.0% | — | ||
| Q3 25 | 66.2% | — | ||
| Q2 25 | 66.1% | — | ||
| Q1 25 | 67.3% | — | ||
| Q4 24 | 69.5% | 70.2% | ||
| Q3 24 | 67.5% | 48.8% | ||
| Q2 24 | 68.2% | 52.5% | ||
| Q1 24 | 67.9% | 72.6% |
营业利润率BOCRGNX
| Q4 25 | -4.2% | -190.0% | ||
| Q3 25 | -3.7% | -176.3% | ||
| Q2 25 | -2.9% | -296.3% | ||
| Q1 25 | -2.9% | 13.6% | ||
| Q4 24 | -4.6% | -242.1% | ||
| Q3 24 | -2.7% | -256.6% | ||
| Q2 24 | -16.2% | -251.3% | ||
| Q1 24 | -8.1% | -408.8% |
净利率BOCRGNX
| Q4 25 | -23.1% | -221.3% | ||
| Q3 25 | -9.0% | -208.3% | ||
| Q2 25 | -8.2% | -331.8% | ||
| Q1 25 | -2.4% | 6.8% | ||
| Q4 24 | 19.1% | -241.3% | ||
| Q3 24 | -5.8% | -246.3% | ||
| Q2 24 | -8.3% | -237.7% | ||
| Q1 24 | -11.0% | -405.4% |
每股收益（稀释后）BOCRGNX
| Q4 25 | $-0.23 | $-1.30 | ||
| Q3 25 | $-0.08 | $-1.20 | ||
| Q2 25 | $-0.07 | $-1.38 | ||
| Q1 25 | $-0.02 | $0.12 | ||
| Q4 24 | $0.17 | $-0.99 | ||
| Q3 24 | $-0.05 | $-1.17 | ||
| Q2 24 | $-0.07 | $-1.05 | ||
| Q1 24 | $-0.09 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $56.8M | $230.1M |
| 总债务越低越好 | $25.7M | — |
| 股东权益账面价值 | $516.1M | $102.7M |
| 总资产 | $713.1M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.05× | — |
8季度趋势，按日历期对齐
现金及短期投资BOCRGNX
| Q4 25 | $56.8M | $230.1M | ||
| Q3 25 | $67.6M | $274.2M | ||
| Q2 25 | $68.6M | $323.3M | ||
| Q1 25 | $69.2M | $267.9M | ||
| Q4 24 | $73.2M | $234.7M | ||
| Q3 24 | $58.6M | $255.5M | ||
| Q2 24 | $53.1M | $290.4M | ||
| Q1 24 | $53.4M | $338.7M |
总债务BOCRGNX
| Q4 25 | $25.7M | — | ||
| Q3 25 | $25.9M | — | ||
| Q2 25 | $26.1M | — | ||
| Q1 25 | $26.3M | — | ||
| Q4 24 | $26.5M | — | ||
| Q3 24 | $26.7M | — | ||
| Q2 24 | $26.9M | — | ||
| Q1 24 | $27.1M | — |
股东权益BOCRGNX
| Q4 25 | $516.1M | $102.7M | ||
| Q3 25 | $528.4M | $161.5M | ||
| Q2 25 | $531.0M | $213.7M | ||
| Q1 25 | $533.3M | $274.2M | ||
| Q4 24 | $532.8M | $259.7M | ||
| Q3 24 | $527.7M | $301.4M | ||
| Q2 24 | $530.5M | $348.3M | ||
| Q1 24 | $536.2M | $390.7M |
总资产BOCRGNX
| Q4 25 | $713.1M | $453.0M | ||
| Q3 25 | $721.4M | $525.2M | ||
| Q2 25 | $730.6M | $581.0M | ||
| Q1 25 | $730.8M | $490.9M | ||
| Q4 24 | $728.3M | $466.0M | ||
| Q3 24 | $711.9M | $519.1M | ||
| Q2 24 | $723.1M | $569.4M | ||
| Q1 24 | $757.3M | $629.2M |
负债/权益比BOCRGNX
| Q4 25 | 0.05× | — | ||
| Q3 25 | 0.05× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.05× | — | ||
| Q2 24 | 0.05× | — | ||
| Q1 24 | 0.05× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-10.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | -33.8% | -174.0% |
| 资本支出强度资本支出/营收 | 93.9% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-17.6M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BOCRGNX
| Q4 25 | $17.9M | $-52.3M | ||
| Q3 25 | $4.9M | $-56.0M | ||
| Q2 25 | $4.6M | $-49.3M | ||
| Q1 25 | $2.6M | $33.6M | ||
| Q4 24 | $21.2M | $-31.6M | ||
| Q3 24 | $5.2M | $-40.5M | ||
| Q2 24 | $4.5M | $-45.5M | ||
| Q1 24 | $2.4M | $-55.5M |
自由现金流BOCRGNX
| Q4 25 | $-10.0M | $-52.8M | ||
| Q3 25 | $-489.4K | $-56.5M | ||
| Q2 25 | $-2.7M | $-49.7M | ||
| Q1 25 | $-4.3M | $32.6M | ||
| Q4 24 | $-11.0M | $-32.7M | ||
| Q3 24 | $-1.2M | $-40.9M | ||
| Q2 24 | $-4.3M | $-46.0M | ||
| Q1 24 | $-6.0M | $-56.0M |
自由现金流率BOCRGNX
| Q4 25 | -33.8% | -174.0% | ||
| Q3 25 | -1.7% | -189.9% | ||
| Q2 25 | -9.7% | -232.8% | ||
| Q1 25 | -15.5% | 36.6% | ||
| Q4 24 | -39.2% | -154.2% | ||
| Q3 24 | -4.4% | -168.9% | ||
| Q2 24 | -15.9% | -206.2% | ||
| Q1 24 | -23.6% | -358.5% |
资本支出强度BOCRGNX
| Q4 25 | 93.9% | 1.7% | ||
| Q3 25 | 18.9% | 1.7% | ||
| Q2 25 | 25.9% | 1.8% | ||
| Q1 25 | 24.7% | 1.2% | ||
| Q4 24 | 115.3% | 5.1% | ||
| Q3 24 | 23.2% | 1.3% | ||
| Q2 24 | 32.6% | 2.1% | ||
| Q1 24 | 33.1% | 3.6% |
现金转化率BOCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | 3.97× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BOC
| Billboard Rentals | $11.9M | 40% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $10.0M | 34% |
| GIG | $7.3M | 25% |
| Other | $608.4K | 2% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
